A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.“Despite being the ...

Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers for Lilly, with demand rising rapidly.However, to maintain its prowess in the ...

Tirzepatide was associated with the highest degree of weight loss compared with placebo and other GLP-1 agonists. There was no difference in the percentage of weight loss at tirzepatide 15 mg and ...

Researchers analyzed data from the US Collaborative Network of TriNetX of 140,308 patients with T2D who were initiated on tirzepatide or a GLP-1 RA between June 1, 2022, and June 30, 2023.

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny.

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was funded by Eli Lilly, the pharmaceutical company that manufactures ...

Tirzepatide, a 39-amino acid synthetic peptide, is a novel compound acting as a dual GIP/GLP-1 receptor agonist. Current clinical practice guidelines recommend basal insulin or GLP-1 receptor ...

Tirzepatide includes blockbuster injected GLP-1 meds Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA first announced two months ago that any shortage of the meds observed during ...